Influence of denosumab on disseminated tumor cells (DTC) in the bone marrow of breast cancer (BC) patients with neoadjuvant treatment: A GeparX translational substudy.

Pauline Wimberger,Jens-Uwe Blohmer,Petra Krabisch,Theresa Link,Marianne Just,Bruno Valentin Sinn,Eike Simon,Christine Solbach,Tanja Fehm,Carsten Denkert,Cristin Kühn,Kerstin Rhiem,Hans Tesch,Sherko Kümmel,A. Petzold,Oliver J. Stoetzer,C. Meisel,Jan Dominik Kuhlmann,Valentina Nekljudova,Sibylle Loibl

Influence of denosumab on disseminated tumor cells (DTC) in the bone marrow of breast cancer (BC) patients with neoadjuvant treatment: A GeparX translational substudy.

2020

580Background: DTCs in the bone marrow are observed in up to 30% at primary diagnosis of BC and their presence is an independent prognostic factor for reduced survival. It was shown that antiresorp...

Keywords:

Oncology
Breast cancer
prognostic factor
Internal medicine
neoadjuvant treatment
Bone marrow
Pathology
Denosumab
tumor cells
Medicine

Correction
Source
Cite
Save

References

Citations